Blueprint Medicines sees significant increase in holdings by US Bancorp DE during 3rd quarter
☀️Trending News Blueprint Medicines ($NASDAQ:BPMC) is a biopharmaceutical company that focuses on developing precision therapies for patients with genomically defined [...]
Blueprint Medicines Receives $120 Price Target and “Moderate Buy” Rating from Analysts
🌥️Trending News Blueprint Medicines ($NASDAQ:BPMC) is a biopharmaceutical company that specializes in developing targeted therapies for patients with genomically defined [...]
Stephens Initiates Rating for Blueprint Medicines Corp, CFO Landsittel Michael Sells $0.42 Million in Company Shares
☀️Trending News Blueprint Medicines ($NASDAQ:BPMC) Corp is a biopharmaceutical company that focuses on developing precision therapies for patients with genetic [...]
Q2 2024 EPS Estimates for Blueprint Medicines Co. Increased by Analyst
☀️Trending News Blueprint Medicines ($NASDAQ:BPMC) Co. (BPMC) is a biopharmaceutical company focused on developing small molecule therapies for patients with [...]
Blueprint Medicines Co. Insider Sells Over $42K In Stock
🌥️Trending News Blueprint Medicines ($NASDAQ:BPMC) Co. is a clinical-stage biopharmaceutical company focused on developing therapies that are designed to target [...]
BLUEPRINT MEDICINES Reports Second Quarter Earnings Results for FY2023 on August 2nd
🌥️Earnings Overview On August 2nd 2023, BLUEPRINT MEDICINES ($NASDAQ:BPMC) announced their second quarter FY2023 earnings results for the period ending [...]
BLUEPRINT MEDICINES Reports 57.5% Increase in Revenue for FY2023 Q2 with USD 57.6 Million Earnings
☀️Earnings Overview For the second quarter of FY2023, BLUEPRINT MEDICINES ($NASDAQ:BPMC) reported a total revenue of USD 57.6 million – [...]
Blueprint Medicines Corp: Assessing the Pathway to Earnings Growth
☀️Introduction: Blueprint Medicines Corp, a renowned biopharmaceutical company, is set to announce its second-quarter earnings results on August 2, 2023, [...]
Diversified Trust Co. Increases Investment in Blueprint Medicines Co.
☀️Trending News Their development pipeline includes therapies for rare genetic diseases such as mastocytosis and systemic mastocytosis, as well as [...]
Blueprint Medicines Receives FDA Label Expansion for Ayvakit
🌥️Trending News Blueprint Medicines ($NASDAQ:BPMC) has recently received approval from the Food and Drug Administration (FDA) for an expanded label [...]
